Funding Opportunity


Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) AND (R21 Clinical Trial Not Allowed)

Targeted PIs:


Biomedical researchers, clinical scientists, mathematicians/statisticians, anthropologists, behavioral scientists, other researchers


National Institute of Allergy and Infectious Diseases (NIAID) is now accepting NEW R01 and R21 proposals in the ongoing effort to investigate SARS-CoV-2. Applications will be handled on an expedited review and award basis to meet the goals of this program.  The research goals of the program are to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly.


Potential applicants are strongly encouraged to contact Scientific/Research staff before submitting an application to either FOA to determine whether or not the proposed work is within the intended scope of the program and whether requested expedited funding is likely to be available.



Areas of high priority include, but are not limited to, the following:

·        Understanding host compartments of viral replication and duration of shedding;

·        Predictors of disease severity and outcome including viral and host determinants of infection, replication, and recovery;

·        Pathophysiology of disease and clinical prognosis associated with viral loads and immune-based biomarkers;

·        Identification of molecular markers of pathogenesis;

·        Studies on the emergence and evolution of SARS-CoV-2, including the identification of factors that affect viral host-range and virulence and changes to the virus that occur over time in circulation;

·        Studies to comprehensively evaluate viral, host, physical, and environmental factors that facilitate efficient human-to-human SARS-CoV2 transmission utilizing novel and/or improved devices, assays, study designs and/or animal models;

·        Modes and duration of person-to-person transmission;

·        Role of different age groups in transmission dynamics;

·        Potential impact on transmission dynamics from host biology/behavior or environmental factors in superspreading events;

·        Importance of asymptomatic transmission;

·        Development of novel assays for assessing infectivity and viability of viral particles collected from the air;

·        Innate, cellular and humoral immune responses to SARS-CoV-2 infection and/or candidate vaccines;

·        Protective or pathogenic B cell or T cell epitopes from individuals exposed to SARS-CoV-2, including identification of immune epitopes that cross-react with other human coronaviruses;

·        Host immune receptor repertoire studies related to understanding protective immunity or disease pathogenesis

·        Computational modeling of the immune response to infection and/or vaccination

·        Screening of potential adjuvants or immune modulators that improve vaccine efficacy, provide prophylactic protection, or limit/prevent severe disease;

·        Mechanisms of immune-mediated pathology or host factors that might predispose to, or prevent, severe infection;

·        Identifying capacity for SARS-CoV-2 and other coronaviruses to infect potential intermediate hosts;

·        Identify diversity of coronaviruses in bats and other wildlife;

·        Improve detection and diagnostic technologies for use in animal surveillance;

·        Discovery of drug targets or novel drug candidates specific for SARS-CoV-2;

·        Host-directed therapies;

·        Broad-spectrum therapeutics against multiple coronavirus strains;

·        Examination of SARS-CoV-2 antiviral activity of existing or candidate therapeutics initially developed for other indications;

·        Combination therapies;

·        Novel antigen design strategies;

·        Novel platforms or delivery approaches;

·        Addition of adjuvants;

·        Evaluate the potential of enhanced disease after vaccination for SARS-CoV-2;




Thank you,



Jeralyn Haraldsen, PhD | Director

University of Vermont

Research Development

Office of the Vice President for Research

340 Waterman | 85 South Prospect Street

Burlington, VT 05405-0160

P: 802-656-2982 | [log in to unmask]


Chair, NORDP Northeast

Region I representative, NORDP Member Services Committee


Our team will be working remotely until further notice.

MS Teams is my preferred platform for video calls.






To unsubscribe from the SPANEWS list, click the following link: